Active surveillance for low-risk localized prostate cancer

ONCOLOGY

Volumn 23, Issue 11, 2009, Pages

  Large, Michael C ^a   Eggener, Scott E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; INCONTINENCE; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; REVIEW; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; URINARY DYSFUNCTION;

EID: 72449187155     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Cooperburg MR, Broering JM, Kantoff PW, et al: Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Urol 178:S14-S19, 2007. (Pubitemid 47224952)
2. Barocas DA, Cowan JE, Smith Jr JA, et al: What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 180:1330-1334, 2008.
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
4. Yin M, Bastacky S, Chandran U, et al: Prevalence of incidental prostate cancer in the general population: A study of healthy organ donors. J Urol 179:892-895, 2008
5. Ries LA, Melbert D, Krapcho M, et al(eds): SEER Cancer Statistics Review, 1975-2005. Based on November 2007 SEER data submission, posted to the SEER website, 2008. Bethesda, Md, National Cancer Institute. Available at http://seer.cancer.gov/csr/1975-2005/. Accessed August 26, 2009.
6. Paquette EL, Sun L, Paquette LR, et al: Improved prostate cancer-specific survival and other disease parameters: Impact of prostate-specific antigen testing. Urology 60:756-759, 2002. (Pubitemid 35300331)
7. Bill-Axelson A, Holmberg L, Filen F, et al: Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100:1154-1164, 2008.
8. Schroder FJ, Jugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009.
9. Wong TY, Mitra N, Hudes G, et al: Survival associated with treatment vs. observation of localized prostate cancer in elderly men. JAMA 296:2683-2693, 2006. (Pubitemid 44917546)
10. Draisma G, Etzioni R, Tsodikov A, et al: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101:374-383, 2009.
11. Miller DC, Gruber SB, Hollenbeck BK, et al: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98:1134-1141, 2006. (Pubitemid 44288788)
12. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-1261, 2008.
13. Freedland SJ, Kane CJ, Amling, et al: Delay of radical prostatectomy and the risk of biochemical progression in men with low risk prostate cancer. J Urol 175:1298-1302, 2006. (Pubitemid 43312973)
14. Warlick C, Trock BJ, Landis P, et al: Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98:355-357, 2006. (Pubitemid 43338215)
15. Stephenson AJ, Klein EA, Kattan MW, et al: Predicting the long-term risk of prostate cancer specific mortality after radical prostatectomy (abstract 5007). J Clin Oncol 27(15S):236s, 2009.
16. Berglund RK, Masterson RA, Vora KC, et al: Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 180:1964-1968, 2008.
17. Sheridan TB, Carter BH, Wang W, et al: Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 179:901-905, 2008.
18. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994. (Pubitemid 24037911)
19. Bastian PJ, Carter BH, Bjartell A, et al: Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 55:1321-1330, 2009.
20. DallEra MA, Cooperburg MR, Chan JM, et al: Active surveillance for early-stage prostate cancer: Review of the current literature. Cancer 112:1650-1659, 2008.
21. Albertsen PC, Hanley JA, Barrows GH, et al: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248-1253, 2005.
22. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005. (Pubitemid 40617061)
23. Johansson JE, Andren O, Andersson SO, et al: Natural history of early, localized prostate cancer. JAMA 291:2713-2719, 2004. (Pubitemid 38725420)
24. Carter BH, Kettermann A, Warlick C, et al: Expectant management of prostate cancer with curative intent: An update of The Johns Hopkins experience. J Urol 178:2359-2365, 2007. (Pubitemid 350052183)
25. DallEra MA, Konety BR, Cowan JE, et al: Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112:2664-2670, 2008. (Pubitemid 351969209)
26. Klotz L: Active surveillance for favorable risk prostate cancer: What are the results, and how safe is it? Semin in Rad Oncol 18:2-6, 2008.
27. van As NJ, Norman AR, Thomas K, et al: Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54:1297-1305, 2008.
28. Van den Bergh RCN, Roemeling S, Roobol MJ, et al: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55:1-8, 2009.
29. Eggener SE, Mueller A, Berglund RK, et al: A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 181:1635-1641, 2009.
30. Roemeling S, Roobol MJ, Vries SH et al: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51:1244-1251, 2007.
31. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24:46-50, 2006.
32. Stephenson AJ, Aprikian AG, Souhami L, et al: Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59:652-656, 2002. (Pubitemid 34461971)
33. Ali K, Gunnar A, Jan-Erik D, et al: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170-174, 2006. (Pubitemid 44901932)
34. Fall K, Garmo H, Andrén O, et al: Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99:526-532, 2007. (Pubitemid 47073555)
35. Latini DM, Hart SL, Knight SJ, et al: The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178:826-832, 2007. (Pubitemid 47224948)
36. Patel MI, DeConcini DT, Lopez-Corona E, et al: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171:1520-1524, 2004. (Pubitemid 38365409)
37. Nakanishi H, Groskopf J, Fritsche HA, et al: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179:1804-1810, 2008.
38. Wang J, Cai Y, Ren C, et al: Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347-8351, 2006. (Pubitemid 44449142)